

- **Name:** Choong-Kun Lee
- **Current Position & Affiliation:** Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
- **Country:** Korea

• Educational Background:

Mar 2015 – Feb 2019	Ph.D. Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea
Sep 2012 – Aug 2014	M.S. Graduate School of Medicine, Yonsei University, Seoul, Korea
Mar 2004 – Feb 2010	M.D., Yonsei University College of Medicine, Seoul, Korea

• Professional Experience:

Mar 2025 – Present	Associate Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
Sep 2021 – Feb 2025	Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
Mar 2020 – Aug 2021	Clinical Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
Mar 2019 – Feb 2020	Clinical Fellow, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine

• Professional Organizations:

• Main Scientific Publications:

1. **Lee CK**, Kim HS, Jung M, Kim H, et al. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. *J Clin Oncol*. 2024 Jan;JCO2300971. doi: 10.1200/JCO.23.00971. PMID: 37883723.
2. **Lee CK**, Chon HJ, Cheon J, Lee MA et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-

institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). *Lancet Gastroenterol Hepatol*. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31.

3. **CK Lee***, SY Rha*, HS Kim, M Jung, B Kang et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. *Nature Communications*. 2022 Oct 12;13(1):6002. doi: 10.1038/s41467-022-33267-z. (*Co-first authors)
4. **CK Lee**, S. H. Jeong, C. Jang, H. Bae, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. *Science* 363, 644-649 (2019).